Earlier studies examining TET2 mutations with bidirectional Sanger sequencing or 454-based NGS failed to detect any TET2 mutations in CBF-AML.23, 24 Of AML cases examined in TCGA, mutation in TET2 was shown in only 1 of 7 cases with t(8;21), and none of 11 cases with inv(16).16 A more recent study based on RNA-sequencing has shown TET2 mutations in 3 of 20 cases with t(8;21), but none in 28 cases with inv(16).15 In this study, we have shown a similar frequency (6/51) of TET2 mutations in t(8;21) and an apparently higher frequency (2/21) in inv(16). The gene discussed is TET2; the disease is acute myeloid leukemia.